HIF1A

Across TCGA pan-cancer cohorts, HIF1A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HIF1A data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HIF1A Mutation is associated with better overall survival. In most high-consensus cancer types, elevated HIF1A expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, LIHC, and KIRP are the cancer types where HIF1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.406	.014	25	view →
LIHC	OS	Median	All	0.167	0.786	<.001	24	view →
KIRP	DFS	Median	All	0.140	0.871	<.001	22	view →
SARC	OS	Median	All	0.164	0.839	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
UCEC	DFS	Median	II,III,IV	0.927	0.437	.029	6	view →
SKCM	DFS	Median	III,IV	0.037	0.602	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HIF1A–BLCA (OS)

Open the BLCA breakdown →